$NMRD Interesting tech play in CGM space. Regulatory challenges but potential game-changer with sugarBEAT. Watching closely for FDA approval and commercial traction. Might be a speculative bet for those with high risk tolerance. Keeping position small but intrigued by their innovative approach. in-depth review of recent trends: https://beyondspx.com/article/navigating-nemaura-medical-s-continuous-growth-journey-a-detailed-analysis-nmrd
$NMRD Nemaura Medical Inc. (NMRD): Navigating the Path to Commercialization https://beyondspx.com/article/nemaura-medical-inc-nmrd-revolutionizing-diabetes-management-through-innovative-technologies
$NMRD Nemaura Medical Inc. (NMRD): Revolutionizing Diabetes Management Through Innovative Technologies https://beyondspx.com/article/nemaura-medical-inc-nmrd-revolutionizing-diabetes-management-through-innovative-technologies
$NMRD Does anyone know if form 25-NSE posted on 3/21 pertains specifically to Nasdaq Cap delisting from January or is this notice of not being traded on any exchange period ?
$NMRD should be getting partnership news with Fiscal year March 31st approaching and authorized shares now approved . Let’s hope this milestone achieved per Faz’s previous interview comments
$NMRD The Next Level in Health Tracking
https://miboko.com/sensors/
Most health trackers measure what you’re doing – like how many steps you take or how many minutes you’re active each day. Our wearable sensor measures what’s actually going on inside your body.
Specifically, it tracks your metabolism, showing you how your body is responding to sugar. Because that’s actually the main influencer of everything from your appetite and weight to how well you sleep, how much energy you have, and even your mood. And longer-term it’s a big factor in chronic diseases like diabetes, heart disease, and dementia.
$NMRD Analyst Edward Woo, Ascendiant
Buy 12/15/23 $3.50
In addition to the medical applications, we have developed Miboko, (www.Miboko.com), a digital healthcare program with the glucose sensor at its heart. We believe Miboko addresses a significant mass market opportunity that we believe could benefit roughly a third to half of the population by using a non-invasive glucose sensor to measure and monitor a user’s metabolic health score, which is based on glucose tolerance or insulin resistance. Those with prediabetes or obesity concerns, or even those looking to maintain better health through more careful glucose control, may benefit from such a metabolic health program. How one’s body metabolizes sugar is the main influencer of one’s appetite, weight, sleep quality, energy, and mood levels and even plays a critical factor in chronic diseases (beyond just diabetes), such as heart disease and dementia.
